Bone Mineral Density
Also written as DXA.
| Osteoporosis / fractures | Reduced bone mineral density | Calcium + vitamin D, weight‑bearing exercise, DEXA screening |
What our notes say
- | Osteoporosis / fractures | Reduced bone mineral density | Calcium + vitamin D, weight‑bearing exercise, DEXA screening | (Malabsorption)
- Bone mineral density 6–12 months after definitive therapy for hyperparathyroidism. (Calcium and parathyroid disorders)
- | Bone mineral density (DXA) | Osteoporosis | T‑score ≤‑2.5 → high fracture risk | (Geriatric medicine)
- | Bone mineral density (if available) | Chronic vitamin D/calcium deficiency | T‑score ≤‑2.5 = osteopenia/osteoporosis | (Nutrition and vitamin deficiencies)
- Indications include symptomatic hypercalcemia, serum calcium >1 mg/dL above normal, reduced bone mineral density (T-score < -2.5), or reduced renal function. (ENDOCRINE PATHOLOGY)
- | Tenofovir disoproxil fumarate (TDF) | Most widely used; also active vs HBV | Nephrotoxicity (proximal tubular dysfunction, Fanconi syndrome) · ↓ bone mineral density | (Pharmco Notes)